Revenue

9 Months Ended

Sep. 30, 2026

Revenue Recognition [Abstract]

Revenue

3. Revenue

Net sales by geography are as follows (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2026		2025		2026		2025
United States	$	1,205.6	$	1,164.0	$	3,655.0	$	3,451.4
International		857.2		837.3		2,671.6		2,536.3
Total	$	2,062.9	$	2,001.4	$	6,326.6	$	5,987.7

Net sales by product category are as follows (in millions):

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2026		2025		2026		2025
Knees	$	767.5	$	792.4	$	2,425.0	$	2,411.2
Hips		536.5		506.2		1,623.2		1,538.1
S.E.T.		578.3		541.5		1,726.5		1,562.6
Technology & Data, Bone Cement and Surgical		180.6		161.3		551.8		475.9
Total	$	2,062.9	$	2,001.4	$	6,326.6	$	5,987.7

S.E.T. includes sales from our Sports Medicine, Biologics, Foot and Ankle, Upper Extremities, Trauma, Craniomaxillofacial and Thoracic ("CMFT") product categories.

This net sales presentation differs from our reportable operating segments, which are based upon our senior management organizational structure and how we allocate resources toward achieving operating profit goals. Each of our reportable operating segments sells all the product categories noted above. Accordingly, the only difference from the presentation above and our reportable operating segments are the geographic groupings.